- Home
- SLDB
as 01-17-2025 4:00pm EST
Solid Biosciences Inc is a life science company. It is engaged in the manufacturing of specialty and generic drugs. The company is involved in curing Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease predominantly affecting boys, with symptoms that usually manifest between three and five years of age. The company's pipeline products are the SB-001 and solid suit. The Company's singular focus is on developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases. The company has categorized its programs into corrective therapies, disease-modifying therapies, and assistive devices.
| Founded: | 2013 | Country: | United States |
| Employees: | N/A | City: | CHARLESTOWN |
| Market Cap: | 124.7M | IPO Year: | 2018 |
| Target Price: | $17.75 | AVG Volume (30 days): | 565.4K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 12 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.91 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.03 - $15.05 | Next Earning Date: | 03-12-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Solid Biosciences Inc. (SLDB)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Tan Kevin | SLDB | CFO & Treasurer | Jan 9 '25 | Sell | $3.89 | 4,073 | $15,849.26 | 24,789 | |
| Hanrahan Jessie | SLDB | Chief Regulatory Officer | Dec 2 '24 | Sell | $5.60 | 4,610 | $25,822.45 | 14,235 | |
| Howton David T | SLDB | Chief Operating Officer | Dec 2 '24 | Sell | $5.60 | 5,072 | $28,396.10 | 15,663 | |
| Herzich Paul | SLDB | Chief Technology Officer | Dec 2 '24 | Sell | $5.60 | 2,777 | $15,550.64 | 12,182 | |
| Cumbo Alexander | SLDB | President and CEO | Dec 2 '24 | Sell | $5.60 | 11,114 | $62,236.18 | 38,484 |
Latest Solid Biosciences Inc. News
SLDB Breaking Stock News: Dive into SLDB Ticker-Specific Updates for Smart Investing
MT Newswires
3 days ago
Solid Biosciences Outlines Key Priorities at Healthcare Conference
GlobeNewswire
3 days ago
Solid Biosciences Outlines Key Priorities for Advancing Diversified Neuromuscular and Cardiac Development Pipeline and Establishing Leadership in Precision Genetic Medicines
GlobeNewswire
10 days ago
Solid Biosciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Zacks
11 days ago
SLDB Stock Up as FDA Clears IND for SGT-212 in Friedreich's Ataxia
MT Newswires
11 days ago
Truist Initiates Solid Biosciences at Buy With $16 Price Target
MT Newswires
11 days ago
Solid Biosciences' Friedreich's Ataxia Treatment Application Gets FDA Clearance; Shares Rise After Hours
GlobeNewswire
11 days ago
Solid Biosciences Announces FDA IND Clearance for First-In-Industry Dual Route of Administration Gene Therapy to Treat Both Neurologic and Cardiac Manifestations of Friedreich’s Ataxia
GlobeNewswire
13 days ago
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Compare SLDB vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "SLDB Solid Biosciences Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.